Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New biomarkers offer hope for early detection and prevention of Alzheimer's

The failure to diagnose Alzheimer's disease, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered a major reason why treatments fail in clinical trials. Previous research to molecularly diagnose Alzheimer's disease yielded "A/T/N" central biomarkers based on the measurements of proteins, β-amyloid ("A") and tau ("T"), and "N" encompassing neurodegeneration. A/T/N can be measured in brain tissue, by in vivo brain imaging techniques, and by analysis of cerebrospinal fluid and plasma.

18 Sep 2024

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.

18 Sep 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

The Key Role of iPSC-Derived Microglia in Research and Drug Discovery

Dr. Tilman explains the functions of iPSC-derived microglia and their relevance to conditions like Alzheimer’s.

From Axol Bioscience Ltd 17 Sep 2024

Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced the launch of its imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay.

From Newcells Biotech 17 Sep 2024

ESMO Congress 2024 to unveil future-focused cancer treatments

The ESMO Congress 2024 will hold a press conference to introduce and discuss the "Eyes to the Future" Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

16 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

QB3-led team awarded $12 million to explore autism origins with advanced models

A QB3-led team uniting researchers from the University of California campuses at Berkeley, San Francisco, and Santa Cruz was awarded a $12 million grant from the California Institute for Regenerative Medicine (CIRM) to investigate the origins of autism using sophisticated cellular models called "neural organoids."

12 Sep 2024

New algorithm unveils key genetic mutations across multiple cancers

A computer algorithm can efficiently find genetic mutations that work together to drive cancer as well as other important genetic clues that researchers might someday use to develop new treatments for a variety of cancers.

11 Sep 2024

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard's Office of Technology Development (OTD) and Boston University (BU)'s Technology Development office for novel molecules that activate the lymphatic system - a first in the pharma industry.

11 Sep 2024

Scripps Research develops breakthrough technique for adding unique amino acids to proteins

It's a dogma taught in every introductory biology class: Proteins are composed of combinations of 20 different amino acids, arranged into diverse sequences like words.

11 Sep 2024

Innovative method unlocks potential for drugging undruggable GTPases

Drugs for the K-Ras oncogene inspire an approach for targeting the GTPases, a family of enzymes whose dysfunction can lead to Parkinson's and many other diseases.

11 Sep 2024

First crystal structure of alternative DNA shape from the insulin gene revealed

The first crystal structure of an alternative DNA shape from the insulin gene has been revealed by a UCL-led research team.

9 Sep 2024

SCIEX summit - Highlighting scientific breakthroughs in mass spectrometry that really count

Join scientists and researchers from around the globe to discuss the importance of LC-MS in fields like food and environmental testing, pharmaceutical and biopharmaceutical discovery and development and biomedical and omics research.

From SCIEX 9 Sep 2024

The impact of microgravity on cancer development and treatment

The Wake Forest Institute for Regenerative Medicine (WFIRM) is honored to announce its selection for a pioneering cancer research project that will take place aboard the International Space Station (ISS). The project, one of only five chosen through a competitive solicitation by the ISS National Lab in partnership with NASA, aims to explore the effects of microgravity on cancer development and treatment.

6 Sep 2024

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics.

5 Sep 2024

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

From ERS Genomics 5 Sep 2024

Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Misha Kudryshev's lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.

4 Sep 2024

Study shows how troriluzole can target early-stage alterations associated with Alzheimer's

In a recent development in Alzheimer's disease research, Auburn University scientists have studied a new drug, troriluzole, that can prevent brain changes leading to memory loss and cognitive decline in a mouse model of the disease.

3 Sep 2024

Drug Discovery News and Research

Further Reading

New biomarkers offer hope for early detection and prevention of Alzheimer's

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

Early specificity testing crucial for antibody drug safety

Ohio State's novel DHODH inhibitor enters first human trials

The Key Role of iPSC-Derived Microglia in Research and Drug Discovery

Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

ESMO Congress 2024 to unveil future-focused cancer treatments

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

QB3-led team awarded $12 million to explore autism origins with advanced models

New algorithm unveils key genetic mutations across multiple cancers

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

Scripps Research develops breakthrough technique for adding unique amino acids to proteins

Innovative method unlocks potential for drugging undruggable GTPases

First crystal structure of alternative DNA shape from the insulin gene revealed

SCIEX summit - Highlighting scientific breakthroughs in mass spectrometry that really count

The impact of microgravity on cancer development and treatment

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Study shows how troriluzole can target early-stage alterations associated with Alzheimer's

ELRIG Drug Discovery: Poster Sessions eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News